Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7228
- Development stage
- Preclinical
- Lead developer
- Guerbet
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
7228 is a novel Ultrasmall Particle of Iron Oxide (USPIO) developed by GUERBET. It functions as an MR imaging contrast agent, specifically designed to visualize atherosclerotic plaques. Preclinical studies in hyperlipidemic rabbits have shown that 7228 is taken up by macrophages within these plaques, leading to detectable susceptibility effects in MR imaging, and demonstrating its potential for functional characterization of plaque activity.
Beyond the preview
Go deeper on 7228.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 7228.